[1] SAUER R,LIERSCH T,MERKEL S,et al.Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years[J].J Clin Oncol,2012,30(16):1926-1933.
[2] ROH M S,COLANGELO L H,O'CONNELL M J,et al.Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum:NSABP R-03[J].J Clin Oncol,2009,27(31):5124-5130.
[3] MARTIN S T,HENEGHAN H M,WINTER D C.Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J].Br J Surg,2012,99(7):918-928.
[4] O'NEILL B D P,BROWN G,HEALD R J,et al.Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer[J].Lancet Oncol,2007,8(7):625-633.
[5] GUNDERSON L L,JESSUP J M,SARGENT D J,et al.Revised TN categorization for colon cancer based on national survival outcomes data[J].J Clin Oncol,2010,28(2):264-271.
[6] PARK Y A,SOHN S K,SEONG J,et al.Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer[J].J Surg Oncol,2006,93(2):145-150.
[7] SAKAI K,KAZAMA S,NAGAI Y,et al.Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions[J].Oncotarget,2014,5(20):9641-9649.
[8] DAHAN L,NORGUET E,ETIENNE-GRIMALDI M C,et al.Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer[J].BMC Cancer,2011,11(1):496.
[9] CECCHIN E,AGOSTINI M,PUCCIARELLI S,et al.Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy[J].Pharmacogenomics J,2011,11(3):214-226.
[10] 江慧洪,王晖,李阿建,等.中性粒细胞/淋巴细胞比值对局部进展期结直肠癌患者预后的影响[J].中华胃肠外科杂志,2017,20(5):550-554.
[11] PINE J K,MORRIS E,HUTCHINS G G,et al.Systemic neutrophil-to-lymphocyte ratio in colorectal cancer:the relationship to patient survival,tumour biology and local lymphocytic response to tumour[J].Br J Cancer,2015,113(2):204-211.
[12] HU B,YANG X R,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J].Clin Cancer Res,2014,20(23):6212-6222.
[13] 李黎,李曙光,闫可,等.外周血淋巴细胞与单核细胞比值变化对食管癌调强放疗预后影响[J].中华放射肿瘤学杂志,2019,28(10):741-745.
[14] NOZOE T,NINOMIYA M,MAEDA T,et al.Prognostic nutritional index:a tool to predict the biological aggressiveness of gastric carcinoma[J].Surg Today,2010,40(5):440-443.
[15] ROELS S,DUTHOY W,HAUSTERMANS K,et al.Definition and delineation of the clinical target volume for rectal cancer[J].Int J Radiat Oncol Biol Phys,2006,65(4):1129-1142.
[16] RYAN R,GIBBONS D,HYLAND J M P,et al.Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J].Histopathology,2005,47(2):141-146.
[17] ONODERA T,GOSEKI N,KOSAKI G.Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients[J].Nihon Geka Gakkai Zasshi,1984,85(9):1001-1005.
[18] DIAKOS C I,CHARLES K A,McMILLAN D C,et al.Cancer-related inflammation and treatment effectiveness[J].Lancet Oncol,2014,15(11):e493-e503.
[19] ABE S,KAWAI K,NOZAWA H,et al.LMR predicts outcome in patients after preoperative chemoradiotherapy for stage II-III rectal cancer[J].J Surg Res,2018,222(5):122-131.
[20] OKUGAWA Y,TOIYAMA Y,OKI S,et al.Feasibility of assessing prognostic nutrition index in patients with rectal cancer who receive preoperative chemoradiotherapy[J].JPEN J Parenter Enteral Nutr,2018,42(6):998-1007.
[21] LI A,HE K,GUO D,et al.Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer[J].Future Oncol,2019,15(28):3233-3242.
[22] DUDANI S,MARGINEAN H,TANG P A,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation[J].BMC Cancer,2019,19(1):664.
[23] WARD W H,GOEL N,RUTH K J,et al.Predictive value of leukocyte-and platelet-derived ratios in rectal adenocarcinoma[J].J Surg Res,2018,232(5):275-282.
[24] PARK I J,YOU Y N,AGARWAL A,et al.Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J].J Clin Oncol,2012,30(15):1770-1776.
[25] 徐莹莹,郭信伟,冀胜军,等.疗前预后营养指数对老年食管鳞癌放疗预后预测价值[J].中华放射肿瘤学杂志,2019,28(9):669-672.
[26] PENG J,ZHANG R,ZHAO Y,et al.Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage Ⅲ colon cancer[J].Chin J Cancer,2017,36(1):96.
[27] NOBLE F,HOPKINS J,CURTIS N,et al.The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer[J].Med Oncol,2013,30(3):596.
[28] GARCIA-MARTINEZ R,ANDREOLA F,MEHTA G,et al.Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J].J Hepatol,2015,62(4):799-806.
[29] PETRELLI F,BARNI S,COINU A,et al.The modified glasgow prognostic score and survival in colorectal cancer:a pooled analysis of the literature[J].Rev Recent Clin Trials,2015,10(2):135-141.
[30] 李涛,吕家华,郎锦义,等.恶性肿瘤放疗患者营养治疗专家共识[J].肿瘤代谢与营养电子杂志,2018,5(4):358-365.
[31] KRATZ F.Albumin as a drug carrier:design of prodrugs,drug conjugates and nanoparticles[J].J Control Release,2008,132(3):171-183.
[32] 王修身,张羲茜,习勉,等.食管鳞癌新辅助放化疗后淋巴细胞下降与病理反应相关性分析[J].中华放射肿瘤学杂志,2019,28(4):274-279. |